AKT1 and leukemia: As demonstrated in our study and others, the high frequency of activation of MAPK/ERK in ALL and PI3K/Akt, specifically in B4 subtype, shows that deregulation of these pathways are key events in the pathogenesis of leukemia, making these proteins candidates for regulatory targeted therapies.